Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 2/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 8/20 | 0.50 |
| ▸ | CTSL | P07711 | 3/20 | 0.49 |
| ▸ | CTSS | P25774 | 3/20 | 0.49 |
| ▸ | CTSK | P43235 | 3/20 | 0.49 |
| ▸ | CTSH | P09668 | 1/20 | 0.49 |
| ▸ | NMUR2 | Q9GZQ4 | 4/20 | 0.48 |
| ▸ | NMUR1 | Q9HB89 | 4/20 | 0.48 |
| ▸ | MC4R | P32245 | 1/20 | 0.48 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL198945 | 0.92 | APLNR (0.53) | APLNROPRM1OPRK1CTSLCTSS | |
| SCHEMBL197746 | 0.86 | OPRM1 (0.54) | APLNROPRM1OPRK1CTSLCTSS | |
| SCHEMBL199036 | 0.86 | CTSL (0.53) | APLNROPRM1OPRK1CTSLCTSS | |
| SCHEMBL4804787 | 0.85 | APLNR (0.55) | APLNROPRM1OPRK1CTSLCTSS | |
| SCHEMBL4804770 | 0.85 | APLNR (0.55) | APLNROPRM1OPRK1CTSLCTSS | |
| SCHEMBL197800 | 0.85 | APLNR (0.49) | APLNROPRM1OPRK1CTSLCTSS | |
| SCHEMBL197807 | 0.85 | OPRM1 (0.53) | APLNROPRM1OPRK1CTSLCTSS | |
| SCHEMBL29634120 | 0.84 | CTSL (0.47) | APLNROPRM1OPRK1CTSLCTSS | |
| SCHEMBL1029282 | 0.84 | OPRM1 (0.52) | APLNROPRM1OPRK1CTSLCTSS | |
| SCHEMBL4303904 | 0.84 | OPRM1 (0.54) | APLNROPRM1OPRK1MC4RC5AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088890-B2 | Peptides and peptidomimetic compounds, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2012-01-03 | — | — | US | disclosed |
| US-20100081787-A1 | PEPTIDES AND PEPTIDOMIMETIC COMPOUNDS, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081787-A1 | PEPTIDES AND PEPTIDOMIMETIC COMPOUNDS, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | NGLY1, GHRHR, GHSR | APLNR 70/4885OPRM1 617/4885OPRK1 855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.